Helen Fisher
Follow
Get notifications in MyBN when activity occurs.
Helen Fisher
Non-Executive Director / Paradigm Biopharmaceuticals
Helen Fisher is the chief executive and managing director of Bio Capital Impact Fund and a director of NovellusDx, a personalised cancer diagnostics company.
Prior to establishing the Bio Capital Impact Fund in 2017, Ms Fisher was a partner of Deloitte and led its life sciences industry practice in Australia for 5 years.
She has provided strategic tax advice to public-listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP management and location, and supply chain management.
Prior to establishing the Bio Capital Impact Fund in 2017, Ms Fisher was a partner of Deloitte and led its life sciences industry practice in Australia for 5 years.
She has provided strategic tax advice to public-listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP management and location, and supply chain management.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1177th | 360 Capital Group | -31% | -6% |
| 1188th | TZ | -31% | -32% |
| 1716th | Calix | -67% | 18% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 638th |  | Calix | $29.3m |
| 746th | | TZ | $13.8m |
| 747th | | 360 Capital Group | $13.8m |
| 749th | | Indoor Skydive Australia Group | $13.6m |
| 750th | | APN Property Group | $13.5m |
1328 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Paradigm Biopharmaceuticals | 13 Apr 2022 |
| NEW ROLE: Non-Executive Director, Calix | 03 Nov 2020 |
| NEW ROLE: Partner, Tax, Deloitte | 03 Aug 2020 |
| NEW ROLE: Non-Executive Director, Sienna Cancer Diagnostics | 03 Aug 2020 |
| NEW ROLE: Non-Executive Director, INOVIQ | 03 Aug 2020 |
